EGFR and non-small cell lung carcinoma: A synergistic effect between tyrosine kinase inhibitors (gefitinib, erlotinib, afatinib and AZD9291) with genistein, as well as other isoflavones (glycitin, daidzin, biochanin A, and formononetin), induces cell death through interactions with the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) cells [18].